Course of Cardiac Magnetic Resonance Imaging Findings in Acute Myocarditis after COVID-19 mRNA Vaccination

Hirotaka Kawauchi, Yuya Mitsuhashi, Shin Nakamura, Risa Ogawa, Tomonori Miyabe, Ken Kato and Hiroyuki Tanaka

Abstract:

Myocarditis is being increasingly reported as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccines. We herein report a case of myocarditis following COVID-19 mRNA vaccination in a man. Cardiac magnetic resonance imaging (CMRI) revealed an area of high signal intensity on short T1 inversion recovery (STIR) and late gadolinium enhancement (LGE), which are characteristic of myocarditis. Follow-up CMRI performed six months later revealed improvement in the myocardial edema and LGE findings. CMRI is a useful non-invasive imaging modality for making an initial diagnosis as well as for follow-up in cases of myocarditis after COVID-19 mRNA vaccination.

Key words: COVID-19 vaccine, myocarditis, cardiac magnetic resonance imaging (CMRI)

(Intern Med 61: 2625-2629, 2022)
(DOI: 10.2169/internalmedicine.9797-22)

Introduction

Previous studies have described several cases of myocarditis following coronavirus disease 2019 (COVID-19) mRNA vaccination. The patients in these reports invariably presented with chest pain, usually two to three days after their second dose of an mRNA vaccine. Various hypotheses have been proposed to explain the mechanism underlying the onset, including the molecular activity of mRNA vaccines, molecular mimicry between the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and self-antigens, and patients’ genetic background (1).

We herein report a case of myocarditis following COVID-19 mRNA vaccination. Previous reports have described the diagnostic value of cardiac magnetic resonance imaging (CMRI). In the present case, special attention was given to the CMRI findings at the patient’s six-month follow-up evaluation.

Case Report

A 27-year-old man with no remarkable medical history presented to the hospital with chest and back pain radiating to the neck. He had received his second dose of a COVID-19 mRNA vaccine (mRNA-1273) three days before the symptom onset. After his second dose, he experienced a fever on the same day, which resolved over the following 24 h. He had no history of smoking or consuming alcoholic beverages but had a brother with acute myocarditis.

In the emergency room, the patient’s electrocardiogram (ECG) showed ST-segment elevation in all the inductions except aVR (Fig. 1). A physical examination revealed a body temperature of 36.1°C, heart rate of 50 beats per minute, blood pressure of 120/93 mmHg, and oxygen saturation of 99% on room air. Acute myocarditis was suspected, but emergency coronary angiography was performed to rule out acute coronary syndrome. Significant stenosis of the coronary arteries was denied, but a left ventriculogram revealed a mildly reduced ejection fraction with hypokinesis of the anterolateral wall region of the apex (Fig. 2). A blood analysis at the initial visit revealed myocardial damage (troponin T 0.687 ng/mL; creatine kinase (CK)-MB 10%) and systemic inflammatory findings (white blood cells 10,400/μL; C-reactive protein 4.16 mg/dL) (Table 1).

COVID-19 was ruled out by a polymerase chain reaction (PCR) panel, and chest X-ray showed mild cardiac enlargement (Fig. 3). Transthoracic echocardiography revealed an
Electrocardiogram findings at presentation. ST-segment elevation was observed in all the inductions except aVR.

Coronary angiogram findings. There was no significant stenosis of the right coronary artery or left coronary artery.

Figure 1. Electrocardiogram findings at presentation. ST-segment elevation was observed in all the inductions except aVR.

Figure 2. Coronary angiogram findings. There was no significant stenosis of the right coronary artery or left coronary artery.

estimated ejection fraction of about 55% with hypokinesis of the lateral wall region. A small amount of pericardial fluid was noted, but there was no significant valvular disease. CMRI revealed areas of high signal intensity on short T1 inversion recovery (STIR) and late gadolinium enhancement (LGE) of the anterolateral and inferolateral left ventricle, which are characteristic of myocarditis (Fig. 4). Paired antibody titers to various viruses to potentially identify the cause of the cardiomyopathy were negative (Table 2). Myocarditis after COVID-19 mRNA vaccination was finally diagnosed.

During follow-up without medical treatment, the CK peaked at 666 U/L, and the ST elevation showed improvement on an ECG. His subjective symptoms resolved by the next day, and he was discharged on day 8 of illness with a good prognosis. Because the local wall hypokinesia remained, beta blockers were administered as cardioprotective agents. At the six-month follow-up examination, the patient was completely asymptomatic, transthoracic echocardiography showed improvement in wall asynergy, and CMRI showed improvement in the STIR and LGE findings (Fig. 5).

Discussion

An important clinical finding of the present study was that CMRI is a useful non-invasive imaging modality for the diagnosis and follow-up of myocarditis after COVID-19 mRNA vaccination. CMRI is used to differentiate and assess the severity of cardiac diseases (2). Furthermore, the distri-
Table 1. Laboratory Data on Admission.

|                      |                      |                      |
|----------------------|----------------------|----------------------|
| **Peripheral blood** |                      |                      |
| WBC                  | 10,400 /μg           | Blood urea nitrogen  |
|                      | 83 %                 | 13.1 mg/dL           |
| Neutrophils          | 2 %                  | Serum creatinine     |
|                      | 6 %                  | 0.88 mg/dL           |
| Lymphocytes          | 9 %                  | Estimated glomerular |
|                      |                      | filtration rate      |
| Red blood cells      | 516x10^6 /μg         | 87 mL/min/1.73 m²    |
| Hb                   | 15.6 g/dL            | Total protein        |
|                      | 9 %                  | 7.2 g/dL             |
|                      |                      | Serum albumin        |
|                      |                      | 4.3 g/dL             |
|                      |                      | Total bilirubin      |
|                      |                      | 1.5 mg/dL            |
| Coagulation          | Activated partial   |
|                      | thromboplastin time  | 25.6 s               |
|                      |                      | 51 IU/L              |
|                      |                      | Aspartate aminotransferase |
|                      |                      | 18 IU/L              |
|                      |                      | Alkaline phosphatase |
|                      |                      | 103 IU/L             |
|                      |                      | Lactate dehydrogenase|
|                      |                      | 236 IU/L             |
|                      |                      | Creatine kinase      |
|                      |                      | 519 IU/L             |
|                      |                      | Creatine kinase MB   |
|                      |                      | 50 IU/L              |
|                      |                      | High-sensitive troponin T |
|                      |                      | 6.087 ng/mL          |
|                      |                      | N-terminal prohormone of brain natriuretic peptide |
|                      |                      | 177 pg/mL            |
|                      |                      | Hemoglobin A1c       |
|                      |                      | 5.2 %                |
|                      |                      | C-reactive protein   |
|                      |                      | 4.16 mg/dL           |
| Biochemistry         | Sodium               | 140 mEg/L            |
|                      | Potassium            | 4.1 mEg/L            |
|                      | Chloride             | 105 mEg/L            |

Figure 3. Chest X-ray findings. Chest X-ray demonstrated mild cardiac enlargement.

The distribution of LGE and myocardial edema can be used to assess disease severity (3). Almost all previous studies of myocarditis after COVID-19 mRNA vaccination have reported using CMRI to detect abnormalities suggestive of myocarditis, such as LGE or myocardial edema (4). Interestingly, in these reports, the distribution of myocardial edema and LGE on CMRI was mostly to the lateral wall, as also seen in other case series with adults and children (5-7). The present case also demonstrated the same distribution, which led to the diagnosis of myocarditis following COVID-19 mRNA vaccination. None of the previous reports examined the long-term course of the CMRI findings. In the present study, CMRI was performed in the acute phase and at the six-month follow-up, with the latter revealing that the active myocarditis noted in the acute phase had resolved. No other abnormalities were found.

Myocardial LGE specifically reflects irreversible myocardial injury (i.e. necrosis and fibrosis) (8). The incidence of cardiovascular events in LGE-positive patients is considerably higher than in LGE-negative patients and plays an important role in predicting the prognosis (9). There are also reports that the gadolinium in LGE CMRI is associated with major adverse cardiovascular events in patients with acute myocarditis (10). Although there are reports of acute myocarditis in which the gadolinium later cleared (11), as in the present case, the mechanism by which the gadolinium is reduced or eliminated in post-acute myocarditis is unknown (12).

The CMRI findings in the present case suggested that myocarditis after COVID-19 mRNA vaccination is reversible. There are currently few reports of changes in CMRI findings over time in cases of myocarditis after COVID-19 mRNA vaccination. Further follow-up studies are therefore needed.

In conclusion, we reported a case of myocarditis following COVID-19 mRNA vaccination. CMRI was useful for diagnosing the disease and in the follow-up. Myocarditis following COVID-19 mRNA vaccination may be reversible. Currently, however, the pathomechanism of myocarditis after COVID-19 mRNA vaccination is still largely unknown, and further research is needed to understand what the long-term clinical outcomes are.

Informed consent was obtained from the patient.
Figure 4. Cardiac magnetic resonance imaging findings on admission. Cardiac magnetic resonance imaging (CMRI) revealed areas of high signal intensity on short T1 inversion recovery (STIR) (A) and late gadolinium enhancement (LGE) (B) in the anterolateral and inferolateral left ventricle, which are characteristic findings of myocarditis.

Table 2. Paired Serum Examination.

|                          | day1 | day60 | day1 | day60 |
|--------------------------|------|-------|------|-------|
| Influenza A              | x16  | x16   |      |       |
| Influenza B              | x8   | x8    | <4   | x4    |
| Adenovirus               | x8   | x8    | Type 4 | <4   | x4    |
| Human parvovirus B19     | 0.29 | 0.33  | Type 16 | x32  | x64   |
| Cytomegalovirus          | x8   | <4    | Type 1 | <4   | <4    |
| Human simplex virus      | x32  | x32   | Type 2 | <4   | <4    |
| Echovirus                |      |       | Type 9 | <4   | <4    |
| Type 9                   | x32  | x32   | Type 11 | <4   | <4    |
| Type 11                  | x32  | x32   | Type 14 | <4   | <4    |
| Type 14                  | <4   | <4    | Type 16 | <4   | <4    |
| Type 16                  | <4   | <4    | Type 22 | <4   | <4    |
| Type 22                  | x4   | x4    |      |       |
Cardiac magnetic resonance imaging (CMRI) revealed that the areas of high signal intensity on STIR (A) and LGE (B) were no longer visible.

The authors state that they have no Conflict of Interest (COI).

References
1. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 144: 471-484, 2021.
2. Russo V, Lovato L, Ligabue G. Cardiac MRI: technical basis. Radiol Med 125: 1040-1055, 2020.
3. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72: 3158-3176, 2018.
4. Gautam N, Saluja P, Fudim M, Jambhekar K, Pandey T, Al’Aref S. A late presentation of COVID-19 vaccine-induced myocarditis. Cureus 13: e17890, 2021.
5. Mouch SA, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine 39: 3790-3793, 2021.
6. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics 148: e2021052478, 2021.
7. Shaw KE, Cavalcante JL, Han BK, Goss M. Possible association between COVID-19 vaccine and myocarditis: clinical and CMR findings. JACC Cardiovasc Imaging 14: 1856-1861, 2021.
8. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53: 1475-1487, 2009.
9. Yoon YE, Kitagawa K, Kato S, et al. Prognostic significance of unrecognized myocardial infarction detected with MR imaging in patients with impaired fasting glucose compared with those with diabetes. Radiology 262: 807-815, 2012.
10. Gräni C, Eichhorn C, Bière L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70: 1964-1976, 2017.
11. Roghi A, Pedrotti P, Milazzo A, Bonacina E, Bucciarelli-Ducci C. Adrenergic myocarditis in pheochromocytoma. J Cardiovasc Magn Reson 13: 4, 2011.
12. Inomata T. Cardiac MRI in the diagnosis of myocarditis. Nihon Shuchu Chiryo Igakkai (J Jpn Soc Intensive Care) Med 18: 8-10, 2011 (in Japanese).